Recent Updates
Recently added Catalysts
CHRS

Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Key Takeaway: REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET
Price reaction · baseline $15.77 (2021-09-09 close) · hit after-hours · 1 other CHRS headline(s) in the window, move may be shared
day 0 close · peak
-2.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+136%
120-day peak, hindsight
Typical move
6.6%
average across 12 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
CHS-0214
Phase 3 · Rheumatoid Arthritis

Full Press Release Details

REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14, 2021, during the virtual conference.
The audio portion of the presentation will be available on the investors’ page of the Coherus Biosciences website at http://investors.coherus.com.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.
Coherus Contact Information:
Coherus BioSciences, Inc.
Last updated: Sep 10, 2021